About Upstream Bio
Upstream Bio is a company based in Waltham (United States) founded in 2021 by Oren Becker.. Upstream Bio has raised $400 million across 2 funding rounds from investors including Orbimed, HBM Healthcare Investments and Enavate Sciences. The company has 52 employees as of December 31, 2024. Upstream Bio offers products and services including Verekitug. Upstream Bio operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Waltham, United States
- Employees 52 as on 31 Dec, 2024
- Founders Oren Becker
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Upstream Bio, Inc.
-
Annual Revenue
$2.37 M-0.42as on Dec 31, 2024
-
Net Profit
$-62.81 M-205.82as on Dec 31, 2024
-
EBITDA
$-77.67 M-93.93as on Dec 31, 2024
-
Total Equity Funding
$400 M (USD)
in 2 rounds
-
Latest Funding Round
$200 M (USD), Series B
Jun 08, 2023
-
Investors
Orbimed
& 12 more
-
Employee Count
52
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Upstream Bio
Upstream Bio is a publicly listed company on the NASDAQ with ticker symbol UPB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Upstream Bio
Upstream Bio offers a comprehensive portfolio of products and services, including Verekitug. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets upstream drivers of inflammatory responses for disease treatment.
Unlock access to complete
Funding Insights of Upstream Bio
Upstream Bio has successfully raised a total of $400M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $200 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $200.0M
-
First Round
First Round
(02 Jun 2022)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Series B - Upstream Bio | Valuation | Enavate Sciences , Venrock | |
| Jun, 2022 | Amount | Series A - Upstream Bio | Valuation | Maruho , Orbimed |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Upstream Bio
Upstream Bio has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, HBM Healthcare Investments and Enavate Sciences. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC & PE firm focused on healthcare sector
|
Founded Year | Domain | Location | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Upstream Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Upstream Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Upstream Bio Comparisons
Competitors of Upstream Bio
Upstream Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Upstream Bio
Frequently Asked Questions about Upstream Bio
When was Upstream Bio founded?
Upstream Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Upstream Bio located?
Upstream Bio is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Upstream Bio a funded company?
Upstream Bio is a funded company, having raised a total of $400M across 2 funding rounds to date. The company's 1st funding round was a Series A of $200M, raised on Jun 02, 2022.
How many employees does Upstream Bio have?
As of Dec 31, 2024, the latest employee count at Upstream Bio is 52.
What is the annual revenue of Upstream Bio?
Annual revenue of Upstream Bio is $2.37M as on Dec 31, 2024.
What does Upstream Bio do?
Upstream Bio was founded in 2021 and is headquartered in Waltham, United States. Therapeutics targeting allergic and inflammatory diseases are developed by the company within the biotechnology sector. Operations focus on monoclonal antibodies, with the lead candidate UPB-101 designed to inhibit the TSLP receptor on various immune cells involved in inflammatory conditions. Research and development activities are centered on advancing these treatments for multiple disease indications.
Who are the top competitors of Upstream Bio?
Upstream Bio's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does Upstream Bio offer?
Upstream Bio offers Verekitug.
Is Upstream Bio publicly traded?
Yes, Upstream Bio is publicly traded on NASDAQ under the ticker symbol UPB.
Who are Upstream Bio's investors?
Upstream Bio has 13 investors. Key investors include Orbimed, HBM Healthcare Investments, Enavate Sciences, Altshuler Shaham, and Venrock Capital Partners.
What is Upstream Bio's ticker symbol?
The ticker symbol of Upstream Bio is UPB on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.